<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977444</url>
  </required_header>
  <id_info>
    <org_study_id>PEE-002-2007</org_study_id>
    <nct_id>NCT00977444</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment</brief_title>
  <acronym>EFO</acronym>
  <official_title>Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucitec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nucitec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract

      Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This
      study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of
      knee.

      A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried
      out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly
      injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8
      mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will
      be the change from baseline to final assessment in the Western Ontario and McMaster
      University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The WOMAC osteoarthritis index is a validated, multidimensional, disease specific, health
      status measure. It probes clinically important patient relevant symptoms in the areas of
      pain, stiffness and physical function in patients with hip and/or knee osteoarthritis. It
      consists of 24 questions in three separated subscales (5 questions on pain subscale, 17
      questions on physical function subscales and 2 questions on stiffness subscale), each scored
      in analog scale from 0 to 10 points (0 representing no pain, 10 representing extreme pain).
      Each subscale score was weighed 10 points, thus 30 was the maximum punctuation for WOMAC
      total score.

      The Lequesne index is a 10-question interview-style survey given to patients with
      osteoarthritis of the knee. It has 5 questions pertaining to pain or discomfort, 1 question
      dealing with maximum distance walked, and 4 questions about daily activities. The total
      questionnaire is scored on a 0 to 24 scale, with lower scores meaning less functional
      impairment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is the change from baseline to final assessment in the Western Ontario and McMastern University OA index (WOMAC), and Lequesne´s functional index.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>kondrium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intraarticular injections once month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>kondrium f</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular injections once month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kondrium</intervention_name>
    <description>intraarticular injections once month</description>
    <arm_group_label>kondrium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>kondrium f</intervention_name>
    <description>intraarticular injections once month</description>
    <arm_group_label>kondrium f</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methyl prednisolone (corticosteroid)</intervention_name>
    <description>intraarticular injections once month</description>
    <arm_group_label>corticosteroid</arm_group_label>
    <other_name>corticosteroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 40 years

          -  symptomatic evidence of OA in the knee for at least 1 year

          -  radiographic evidence of Kellgren and Lawrence grade II to IV OA of the knee

          -  no intra-articular injection of corticosteroids within the last 3 months

        Exclusion Criteria:

          -  any history of adverse reaction to the study drugs

          -  current pregnancy status

          -  uncontrolled hypertension

          -  active infection

          -  undergone surgery/arthroscopy within three months

          -  diagnosis of radiographic OA of Kellgren and Lawrence grade I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Amador, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Jose</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital San Jose</name>
      <address>
        <city>Queretaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sandra Garcia</name_title>
    <organization>Cindetec</organization>
  </responsible_party>
  <keyword>knee</keyword>
  <keyword>osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

